If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnimalcare Grp Regulatory News (ANCR)

Share Price Information for Animalcare Grp (ANCR)

Share Price is delayed by 15 minutes
Get Live Data
333.50    0.00 (0.00%)
Bid:
332.00
Ask:
335.00
Spread: 3.00 (0.904%)
Market Cap: £230.27m
ANCR Live PriceLast checked at - London Stock Exchange

Intraday Animalcare Grp Share Chart

Form 8.5 (EPT/RI)

24 Jun 2026 10:38

RNS Number : 5869J
Panmure Liberum Limited
24 June 2026
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Panmure Liberum Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Animalcare Group plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Animalcare Group plc

(d) Date dealing undertaken:

23 Jun 2026

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

20p ordinary

Purchase

3,514

3.32351 GBP

3.3233 GBP

20p ordinary

Sales

25,000

3.325 GBP

3.325 GBP

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing, or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

 

Date of disclosure:

24/06/2026

Contact name:

Shivani Ghiraiya

Telephone number:

+44 (0) 20 3100 2213

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERFZGZVLDVGVZG
Date   Source Headline
23rd Mar 20217:00 amRNSNotification of major holding
18th Feb 20214:36 pmRNSPrice Monitoring Extension
18th Feb 20213:43 pmRNSDaxocox receives positive opinion from CVMP in EU
8th Feb 20212:46 pmRNSNotification of major holding
1st Feb 20217:00 amRNSAppointment of Nominated Advisor and Joint Broker
21st Jan 20217:00 amRNSTrading Update and Notice of Full Year Results
18th Nov 20207:00 amRNSGrant of options
29th Sep 20207:00 amRNSInterim Results H1 2020
28th Sep 20207:00 amRNSAnimalcare and Kane Biotech to target biofilms
23rd Jul 20207:00 amRNSTrading Update and Notice of Results
30th Jun 20204:00 pmRNSResult of AGM 2020
9th Jun 20203:55 pmRNS2019 Annual Report and Notice of 2020 AGM
28th May 20207:00 amRNSFull year results 2019
18th May 202011:20 amRNSNotice of Full Year 2019 Results
25th Mar 20207:00 amRNSTrading update, revised date for full year results
23rd Jan 20207:00 amRNSTrading Update & Notice of Results
17th Jan 20208:55 amRNSHoldings in Company
24th Sep 20197:00 amRNSHalf Year Results
25th Jul 20197:00 amRNSDirectorate Change
23rd Jul 20197:00 amRNSTrading Update & Notice of Results
16th Jul 201911:37 amRNSNotification of major holdings
25th Jun 20191:40 pmRNSResult of AGM
19th Jun 20193:52 pmRNSBoard change
10th Jun 20192:55 pmRNSDirector/PDMR Shareholding
22nd May 20197:00 amRNSAnnual Report and Notice of Annual General Meeting
8th May 201910:35 amRNSDividend Declaration
30th Apr 20197:00 amRNS2018 Full Year Results
21st Jan 20197:00 amRNSTrading Update and Notice of Results
30th Oct 20187:50 amRNSAdditional Listing
1st Oct 201812:45 pmRNSAdditional Listing
25th Sep 20185:36 pmRNSDividend Declaration
25th Sep 20187:00 amRNSHalf Year Results
4th Sep 20187:41 amRNSAnimalcare announces sale of Wholesale Division
29th Aug 20185:16 pmRNSHolding(s) in Company
3rd Aug 20187:01 amRNSTrading update & Notice of Results
3rd Aug 20187:00 amRNSAnimalcare announces leadership change
9th Jul 20187:00 amRNSCortacare receives positive opinion from CVMP
27th Jun 20182:18 pmRNSResult of AGM
15th Jun 201811:05 amRNSAdditional Listing
30th May 20181:17 pmRNSAnnual Financial Report & Notice of AGM
15th May 20187:00 amRNSFinal Results
26th Apr 20187:00 amRNSDirectorate Change
18th Apr 20182:05 pmRNSSecond Price Monitoring Extn
18th Apr 20182:00 pmRNSPrice Monitoring Extension
18th Apr 20187:00 amRNSTrading update
26th Feb 201811:23 amRNSAdditional Listing
22nd Jan 20187:00 amRNSTrading update & Notice of Results
26th Sep 20177:01 amRNSDirectorate Change
26th Sep 20177:00 amRNSResults for 12 months ended 30 June 2017
20th Sep 20175:03 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.